BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 506 filers reported holding BIO-TECHNE CORP in Q2 2021. The put-call ratio across all filers is 2.08 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,513,060 | -16.6% | 22,228 | 0.0% | 0.77% | -13.1% |
| Q2 2023 | $1,814,472 | +10.0% | 22,228 | 0.0% | 0.88% | +1.3% |
| Q1 2023 | $1,649,095 | -20.1% | 22,228 | -10.8% | 0.87% | +4.3% |
| Q4 2022 | $2,064,292 | +16.2% | 24,907 | +298.0% | 0.84% | -16.4% |
| Q3 2022 | $1,777,000 | -18.1% | 6,258 | 0.0% | 1.00% | -14.4% |
| Q2 2022 | $2,169,000 | -20.0% | 6,258 | 0.0% | 1.17% | -11.2% |
| Q1 2022 | $2,710,000 | -22.2% | 6,258 | -7.0% | 1.32% | -9.4% |
| Q4 2021 | $3,482,000 | +6.5% | 6,731 | -0.3% | 1.45% | +2.2% |
| Q3 2021 | $3,271,000 | +7.6% | 6,751 | 0.0% | 1.42% | +10.3% |
| Q2 2021 | $3,040,000 | +17.2% | 6,751 | -0.5% | 1.29% | +11.5% |
| Q1 2021 | $2,593,000 | +10.8% | 6,788 | -7.9% | 1.16% | -5.2% |
| Q4 2020 | $2,341,000 | +27.0% | 7,372 | -0.9% | 1.22% | +14.6% |
| Q3 2020 | $1,843,000 | -8.4% | 7,438 | -2.4% | 1.06% | -2.7% |
| Q2 2020 | $2,013,000 | +38.7% | 7,622 | -0.4% | 1.09% | +9.4% |
| Q1 2020 | $1,451,000 | -23.0% | 7,652 | -10.9% | 1.00% | -3.8% |
| Q4 2019 | $1,884,000 | +12.1% | 8,585 | 0.0% | 1.04% | +1.9% |
| Q3 2019 | $1,680,000 | -6.1% | 8,585 | 0.0% | 1.02% | -6.8% |
| Q2 2019 | $1,790,000 | -9.3% | 8,585 | -13.7% | 1.09% | -12.0% |
| Q1 2019 | $1,974,000 | +37.2% | 9,944 | 0.0% | 1.24% | +30.7% |
| Q4 2018 | $1,439,000 | -29.1% | 9,944 | 0.0% | 0.95% | -28.9% |
| Q3 2018 | $2,030,000 | +38.0% | 9,944 | 0.0% | 1.34% | +18.9% |
| Q2 2018 | $1,471,000 | – | 9,944 | – | 1.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |